News Releases

Taiho Pharmaceutical's press releases may contain information about prescription drugs including products currently under development, however information contained in the press releases are not intended to constitute promotion, advertisement, or medical advice.

2021 RSS

December 21, 2021

Taiho Pharmaceutical to Provide Matching Funds to Three Crowdfunded Projects Addressing Issues in the Field of Oncology　"The First Taiho Smile Support"
November 30, 2021

Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences'Anti-TIGIT Program in Japan and Certain Territories in Asia（PDF：500.3 KB）
November 25, 2021

Taiho and Meiji Announce the Launch of Bilanoa_® OD Tablets 20mg,Anti-allergy Drug in Japan（PDF：159.8 KB）
November 24, 2021

Taiho Pharmaceutical Launches BUP-4 LADY_®, Japan's First OTC Medication Indicated for Urinary Urgency
November 04, 2021

Otsuka Group Supports Recommendations of the Task Force on Climate-related Financial Disclosure (TCFD) -Joins TCFD Consortium-（PDF：214.5 KB）
September 14, 2021

Taiho Pharmaceutical Submits New Drug Application for its HSP90 Inhibitor Pimitespib (TAS-116) for GIST
September 06, 2021

"Efil" Virus Removal/Antibacterial Spray Marks Its Debut Outside Japan, to Support Peace of Mind in Daily Life for People in Singapore "Turn your life around with Efil"
September 06, 2021

Taiho Pharmaceutical Relocates Head Office
September 01, 2021

Taiho Pharmaceutical's Drug Discovery Site in Tsukuba Fully Switches to Carbon-Neutral Electricity, and Newly Adopts Carbon Neutral City Gas
Annual CO₂ Emissions of the Tsukuba Area to Decline by Approximately 56% （PDF：100.8 KB）
September 01, 2021

100th Anniversary of Otsuka Group of Companies Looking Ahead to the Next 100 Years
July 01, 2021

Taiho Pharmaceutical to Provide Matching Funds to Select Crowdfunded Projects Addressing Issues in the Field of Oncology with New Taiho Smile Support Program
June 09, 2021

Taiho Pharmaceutical Adopts Carbon-Neutral Electricity at Inuyama Plant（PDF：124.7 KB）
June 09, 2021

Otsuka Group Complete Introduction of CO₂-free Electricity for All 23 Manufacturing Facilities in Japan -Contributing to a more than 40% reduction in annual CO₂ emissions in Japan-
May 27, 2021

Taiho Pharmaceutical Obtains Approval for an Additional Dosage and Administration of 5-HT₃ Receptor Antagonist Aloxi^® for Pediatric Patients in Japan（PDF：177.8 KB）
May 10, 2021

Taiho Pharmaceutical Launches New VR Content, "Virtual Patient's Journey" for Doctors, a Simulation of a Palmoplantar Pustulosis Patient's Struggles and Difficulties in Everyday Life
April 02, 2021

FDA Grants Breakthrough Therapy Designation for Taiho Pharmaceutical Originated Futibatinib for Treatment of Advanced Cholangiocarcinoma（PDF：433.6 KB）
March 23, 2021

Taiho Pharmaceutical Submits New Drug Application for NK₁ Receptor Antagonist Fosnetupitant for Prevention of Gastrointestinal Symptoms (Nausea and Vomiting) Associated with Cancer Chemotherapy
March 09, 2021

Taiho Pharmaceutical Announces Personnel Changes（PDF：82.6 KB）
February 22, 2021

Taiho Pharmaceutical's TAS-116, an Oral HSP90 Inhibitor, Shows Significantly Prolonged
Progression-Free Survival in Patients with GIST in Phase-III Clinical Trial
February 09, 2021

Office Divisions of Five Otsuka Group Companies to Switch to Green Power（PDF：102.5 KB）
January 18, 2021

Taiho Pharmaceutical Launches Its First Food with Function Claims Product to Counter Cold Hands Among Women
January 15, 2021

Taiho Pharmaceutical Announces Establishment of a New Company as a Clinical Development and Commercial Base in Switzerland
January 13, 2021

Taiho and Astex Extend Strategic Oncology Collaboration with MSD
Granting Exclusive License to SHP2 Program
January 12, 2021

Taiho Pharmaceutical Fully Adopts Carbon-Neutral Electricity at Saitama Site（PDF：127.2 KB）
January 05, 2021

Taiho Pharmaceutical Begins Phase III Clinical Trial with Therapeutic Drug for Duchenne Muscular Dystrophy (TAS-205) in Japan

News Releases